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Introduction
Male breast carcinoma (MBC) is rare and represents less
than 1% of all mammary carcinomas [1]. Although less fre-
quent, it tends to be more aggressive than its female
counterpart [2,3]. One of the reasons for this is the rela-
tively small size of the male breast, which may permit
earlier and/or easier access for the tumor cells to the
chest wall. Because of the rarity of the disease, random-
ized clinical trials have not been performed and the treat-
ment of MBC has not been standardized [4]. MBCs are
treated, like female breast carcinomas (FBCs), with radical
mastectomy followed by adjuvant chemotherapy and radi-
ation. Tamoxifen has also been used in estrogen receptor
(ER)-positive cases.
It is presumed that MBC is biologically similar to FBC.
However, there are differences between the two: a higher
frequency of expression of ER (81%) and progesterone
receptor (PR) (74%) is in MBC (for review see [5]). In
contrast to women, men do not have a higher incidence of
ER-positive tumors with advancing age. The relationship of
ER with overall survival is uncertain. In a multi-institutional
study, Donegan and colleagues [6] found that ER was
associated with better survival; however, in a series of
229 patients from the Princess Margaret Hospital no sig-
nificance was found in multivariate analysis [7]. Wang-
Rodriguez and colleagues found better survival in
ER-positive patients but did not find a benefit from treat-
ment with Tamoxifen [8]. Proliferative activity is higher in
AR = androgen receptor; ER = estrogen receptor; FBC = female breast carcinoma; MBC = male breast carcinoma; PR = progesterone receptor;
PSA = prostate-specific antigen; PSAP = prostate-specific acid phosphatase.
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Abstract
Background: The androgen-regulated proteins prostate-
specific antigen (PSA) and prostate-specific acid phosphatase
(PSAP) are present in high concentrations in normal prostate
and prostatic cancer and are considered to be tissue-specific
to prostate. These markers are commonly used to diagnose
metastatic prostate carcinoma at various sites including the
male breast. However, expression of these two proteins in
tumors arising in tissues regulated by androgens such as male
breast carcinoma has not been thoroughly evaluated.
Methods: In this study we analyzed the expression of PSA,
PSAP and androgen receptor (AR) by immunohistochemistry in
26 cases of male breast carcinomas and correlated these with
the expression of other prognostic markers.
Results: AR, PSA and PSAP expression was observed in
81%, 23% and 0% of carcinomas, respectively. Combined
expression of AR and PSA was observed in only four tumors.
Conclusion: Although the biological significance of PSA
expression in male breast carcinomas is not clear, caution
should be exercised when it is used as a diagnostic marker of
metastatic prostate carcinoma.




ER+/PR+ MBCs than in ER–/PR– tumors [9]. More
recently, Pich and colleagues [4] found no correlation
between the expression of ER, PR or androgen receptor
(AR) with overall survival. They concluded that MBCs are
biologically different from FBCs and questioned the ratio-
nale for the use of anti-hormonal (Tamoxifen) therapy in
MBCs.
The male sex hormones (5α-androstan-3α,17β-diol dipro-
pionate; 2α-methyl dihydro testosterone; and testosterone
propionate) have been shown to cause regression of
7,12-dimethylbenz[a]anthracene-induced breast cancers
in rats [10] and to suppress the growth of breast cancer
cell lines. Additionally, an increased risk of breast cancer
is seen in patients with hypoandrogenism and gynecomas-
tia. They have therefore been considered protective
agents in the etiopathogenesis of male breast cancer
[5,6,11]. Androgens in the prostate stimulate the secre-
tion of androgen-dependent proteins such as prostate-
specific antigen (PSA) and prostate-specific acid
phosphatase (PSAP). Similarly, the production of PSA is
seen in some breast cancer cell lines after treatment with
androgens [12,13], suggesting an intact androgen
pathway. In this retrospective study we attempt to analyze
the functional status of the AR pathway in MBCs by
assessing the expression of the androgen-regulated pro-
teins PSA and PSAP.
Materials and methods
Twenty-six cases of MBC were retrieved from the archives
of the Department of Pathology at Northwestern Memorial
Hospital and Lakeside VA Hospital, Chicago, IL, between
the years 1977 and 1999. Clinical charts were reviewed
to obtain follow-up information. Archival paraffin slides
were reviewed to confirm histologic grade in accordance
with the modified Scarff–Bloom–Richardson system [14].
Data about the expression status in these tumors of
ER/PR, Her-2/Neu, epidermal growth factor receptor and
Ki-67 were also available for comparison.
One block from each case was selected to analyze the
expression of PSA, PSAP and AR on serial sections by
immunohistochemical methods. Paraffin-embedded sec-
tions (4 µm thick) after peroxide blocking (3% hydrogen
peroxide in methanol) and antigen retrieval (a microwave
oven pressure cooker with Citra [BioGenex®]) were incu-
bated with serum block to reduce non-specific staining
before exposure to the primary antibody. Polyclonal anti-
bodies against PSA and PSAP (both from Dako Corp®;
1:1800), and monoclonal antibody against AR (Novocas-
tra®, 1:10) were used. Biotin-labeled secondary antibody
and ABC complex (Vector®) followed by exposure to
diaminobenzidine tetrahydrochloride (Sigma Corp®) were
used to detect the antigen. The slides were counter-
stained with hematoxylin and mounted in Permount. Phos-
phate-buffered saline and rabbit or mouse isotypic
antibody were used to confirm specificity of the staining.
Normal prostatic tissue (from other patients) was used for
positive control for AR, PSA and PSAP.
The criteria used to evaluate expression were as follows.
Expression of PSA and PSAP was classified as focal or
diffuse depending on the fraction of the tumor cells
stained. The criteria for AR positivity were based on the
intensity and percentage of tumor cells showing expres-
sion. The intensity was graded as negative, weak, moder-
ate or strong. Tumors that had more than 10% of cells
exhibiting moderate or strong intensity of expression were
considered positive.
We reviewed the databases of the Northwestern Memorial
Hospital as well as Lakeside VA Hospital to obtain the
follow-up information of MBC. Follow-up information was
available for 17 cases. The overall follow-up ranged from
12 to 168 months; the median follow-up was 48 months.
The expression of the antigens was correlated with clinical
and histological features including tumor grade, mitotic
activity, tumor size, histological grade, steroid receptors,
axillary lymph node status, and clinical outcome. Signifi-
cance of the association was assessed by the χ2 test for
independence with the use of the Prophet® Statistical
Program (BBN Systems and Technology). P values less
than 0.05 were considered significant.
Results
Histologically, 25 of the tumors were infiltrating ductal car-
cinomas; the remaining tumor was an infiltrating lobular
carcinoma. Three cases were grade I, 11 cases were
grade II and 12 cases were grade III (Table 1). AR-positive
cases were histologically classified as grade I (3 of
3 cases), grade II (7 of 11 cases) and grade III (9 of
12 cases). ER was expressed in 22 of the 26 cases
(84.6%), whereas PR expression was seen in 13 cases
(50%). All the cases that expressed PR were ER-positive.
Expression of Her-2 was seen in 18 cases, epidermal
growth factor receptor in 12 cases and p53 in one case.
Ki-67 expression in more than 30% of the cells was seen
in 21 cases. Of the 19 cases with axillary dissection,
10 showed lymph node metastases.
AR expression, like that of ER and PR, was seen in the
nuclei of breast epithelial cells (Fig. 1) and in scattered
stromal cells. The expression in tumor cells was seen in
19 of 26 cases (73%).
In contrast, PSA expression was cytoplasmic (Fig. 2).
Normal breast tissue, both ducts and stromal elements
(including adipocytes and vascular endothelium), did not
show any expression of this protein. Expression was
observed in six (23%) cases of tumors; five of these
(19%) showed focal expression, and one (4%) demon-
Breast Cancer Research    Vol 6 No 1 Kidwai et al.
R20
strated diffuse staining. These PSA-positive cases were
histologically grade II and III tumors (three cases each).
PSAP expression was not detected in any of the cases
studied.
Correlation between the expression of PSA and AR with
other parameters is shown in Tables 2 and 3 respectively.
PSA expression was not correlated with AR expression
(P = 0.61), ER (P = 0.16), or PR (P = 0.35). Similarly,
expression of AR did not correlate with any of these para-
meters. Neither of these markers (PSA and AR) was sig-
nificantly associated with positive lymph node status.
There was no significant association of PSA or AR with
overall follow-up, and neither was able to predict the clini-
cal behavior in these patients.
Discussion
Because MBC is rare, it has often been suggested that
metastatic carcinoma from other sites should be consid-
ered before diagnosis of a primary tumor [15]. Prostatic
carcinoma is one of the many primary sites from which
metastases can arise. It has been suggested that immuno-
histochemistry should be performed to rule out this possi-
bility [15]. In the present study we demonstrated the
expression of PSA in 6 of 26 cases of MBC. We were
unable to observe any expression of PSAP in these cases.
Similar findings were reported by Gatalica and colleagues
[16] in their cases of MBC and gynecomastia. Cho and
Epstein [17] reported coexpression of PSAP and PSA in
23 of 25 cases of metastatic prostatic carcinoma involving
supra-diaphragmatic lymph nodes. Taken together, these
findings suggest that PSAP might be a better marker for
excluding metastases from a prostatic primary at this site.
The reasons for the differential expression of PSA and
PSAP are not known; however, similar divergence of
expression has previously been recorded.
PSA and PSAP are androgen-regulated proteins and are
thought to be relatively specific to the prostate. Although
serum PSA in males is predominantly derived from the
Table 1
Correlation of histological grade of male breast carcinoma with expression of androgen receptor (AR), prostate-specific antigen
(PSA), and prostate-specific acid phosphatase (PSAP)
ER PR Her-2 P53 AR PSAP PSA
Grade + – + – + – + – + – + – + –
I 3 0 2 1 0 3 0 3 3 0 0 3 0 3
II 16 2 14 4 2 16 0 18 7 11 0 18 3 15
III 19 2 12 9 5 16 1 20 9 12 0 21 3 18
Figure 1
Nuclear expression of androgen receptor in a case of male breast
carcinoma. High magnification.
Figure 2
Male breast carcinoma showing cytoplasmic expression of prostate-
specific antigen. Medium magnification.
prostate, there are additional sources of this protein: low
levels are found even in females [18–20]. PSA has been
shown to be present in several sites including salivary
glands and the breast. Whether PSA is expressed in
normal healthy breast is controversial [21], although Yu
and colleagues [22], using quantitative methods and poly-
merase chain reaction, were able to demonstrate PSA in
normal breast tissues in 33% of cases. PSA has been
demonstrated in milk from lactating breast [18–20], in
nipple aspiration fluid [23], and in apocrine foci within
fibrocystic disease of the breast [24] in addition to breast
cancer (for review see [25]). In male breast, Gatalica and
colleagues [16] have reported focal strong PSA expres-
sion in normal and hyperplastic ductal epithelium in 5 of
18 cases of gynecomastia. In our study we did not
observe any immunoreactivity for PSA in peritumoral
breast tissues.
PSA from breast tumors has the same molecular charac-
teristics as seminal or prostatic PSA. In the prostatic
secretions PSA is important in the dissolution of the gel
structure of freshly ejaculated semen [26], through the
specific proteolysis of both high molecular mass
semenogelin and fibronectin. PSA, like some other pro-
teases, can also digest other substrates. It can, for
example, digest insulin-like growth factor-binding proteins,
leading to the release of these growth factors [27]. Simi-
larly, digestion of the basement membrane and extracellu-
lar matrix proteins might facilitate cell migration and
invasion [27]. However, PSA has also been shown to
inhibit the endothelial cell response to angiogenic stimula-
tion by fibroblast growth factor-2 and vascular endothelial
growth factor [28]. It has been suggested that PSA might
be an endogenous anti-angiogenic compound. This might
contribute to the association between PSA and prognosis
seen in some studies [29,30].
PSA expression in FBC has been associated with younger
age [31,32] in some studies but with postmenopausal
status in others [33]. Alanen and colleagues [33] and
Howarth and colleagues [34] found a correlation of PSA
expression in FBCs with differentiated tumor types and




Patient characteristics and correlation with prostate-specific
antigen (PSA) in male breast cancer
PSA-positive PSA-negative
Variable Value cases cases P
Age (years) ≤ 65 1 7 0.39
> 65 4 12
Tumor size (cm) ≤ 2 3 6 0.36
> 2 3 14
LN status Positive 3 7 0.604
Negative 2 7
Tumor grade I 0 3 0.52
II and III 6 17
Histological type Ductal 6 19 –
Lobular 0 1
ER Positive 4 18 0.164
Negative 2 2
PR Positive 2 11 0.35
Negative 4 9
AR Positive 4 11 0.61
Negative 2 9
C-erb-b2 Positive 4 14 0.82
Negative 2 6
p53 Positive 1 0 0.06
Negative 5 20
AR, androgen receptor; ER, estrogen receptor; LN, lymph nodes; PR,
progesterone receptor.
Table 3
Association between androgen receptor (AR) and other factors
for male breast cancer
AR-positive AR-negative
Variable Value cases cases P
Age (years) ≤ 65 6 2 0.24
> 65 8 8
Tumor size (cm) ≤ 2 4 3 0.79
> 2 9 8
LN status Positive 6 4 0.65
Negative 4 5
Grade I 2 1 0.73
II and III 13 10
Histological type Ductal 15 10 –
Lobular 0 1
ER Positive 12 10 0.44
Negative 3 1
PR Positive 8 5 0.69
Negative 7 6
C-erb-b2 Positive 9 8 0.1
Negative 6 3
p53 Positive 1 0 0.38
Negative 14 11
ER, estrogen receptor; LN, lymph nodes; PR, progesterone receptor.
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reported that the presence of PSA was significantly asso-
ciated with smaller tumors, tumors with low S-phase frac-
tion, diploid tumors, younger patient age, and tumors with
lower cellularity. In their study, PSA expression was asso-
ciated with good prognosis in FBC even after multivariate
analysis. All the MBC cases in our study that expressed
PSA were histologically of grade II or III. Our study,
although limited by size and follow-up information, could
not identify a prognostic role for PSA.
PSA expression in FBCs is strongly correlated with
expression of ER and AR. Most PSA-producing FBCs are
positive for steroid hormone receptor (ER/AR), but not all
tumors that are positive for steroid hormone receptors
produce PSA [35]. Hall and colleagues [36] have
reported an even stronger association of AR and PSA
expression with AR expression seen in 98% of FBCs
expressing PSA. In the present study, of the six cases that
were positive for PSA, AR expression was seen in only
four. These observations are consistent with the hypothe-
sis [4] that MBC is biologically different from FBC. The
presence of PSA expression in breast carcinomas (both
FBCs and MBCs) in the absence of AR expression would
suggest the presence of an AR-independent pathway for
PSA expression. Yu and colleagues [37] have shown the
expression of PSA in normal breast tissue from a woman
taking Brevicon, a progesterone-containing contraceptive.
Of the two cases in our series that were PSA+/AR+, only
one was PR+. However, both expressed ER. This is con-
sistent with the reported expression of PSA in breast
cancer cell lines after stimulation by norethindrone or
ethinylestradiol [37].
The expression of AR in FBC, although not associated
with smaller tumor size or negative lymph node status
[38,39], is significantly associated with longer disease-
free and/or overall survival [40–43]. This has been sug-
gested to be due in part to its association with ER status
and therefore its better response to hormone therapy
[40,41,44]. In MBC, the relationship between AR and ER
is more variable, from positive association [4,45] to no
association (this study), and even a significant inverse cor-
relation [46]. Additionally, ER status in MBCs, in contrast
to FBCs, does not seem to have a significant effect on
prognosis [4,47]. Although this might be due in part to a
higher frequency of expression, it has been suggested that
ERs in MBCs do not have the same function as in FBCs
[48].
Conclusion
In the present study the expression of PSAP was not
observed in any of the 26 cases examined; this suggests
that this marker might have a greater utility in distinguish-
ing primary breast carcinomas from metastatic prostatic
tumors. Further studies to confirm these findings are nec-
essary. Male breast cancers can express PSA. The
expression of PSA did not correlate with AR expression,
suggesting the existence of alternative pathways for the
control of PSA expression. The expression of neither of
the two proteins was correlated with other clinical and
pathologic tumor parameters. These observations are
unlike those seen in FBCs and support the contention that
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